Associated Papers
Interleukin-36 receptor antagonist deficiency patient with a novel mutation.
Sezer M et al.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie, 2026
Cutaneous findings and treatments in deficiency of interleukin-36 receptor antagonist (DITRA): A review of the literature.
Okorie CL et al.
Experimental Dermatology, 2024
In Silico and In Vitro Analysis of IL36RN Alterations Reveals Critical Residues for the Function of the Interleukin-36 Receptor Complex.
Hassi NK et al.
The Journal of Investigative Dermatology, 2023
A viewpoint on the genetic determinants of generalised pustular psoriasis.
Capon F
Experimental Dermatology, 2023
SARS-CoV-2 infection inducing severe flare up of Deficiency of Interleukin Thirty-six (IL-36) Receptor Antagonist (DITRA) resulting from a mutation invalidating the activating cleavage site of the IL-36 receptor antagonist.
Bozonnat A et al.
Journal of Clinical Immunology, 2021
Mutation in IL36RN impairs the processing and regulatory function of the interleukin-36-receptor antagonist and is associated with DITRA syndrome.
Bal E et al.
Experimental Dermatology, 2019
Select a paper to view details